All research presented at ACG 2025 is strictly embargoed until 12:00 pm local Arizona Time, which aligns with Pacific Daylight Time (PDT)/3:00 pm ET on Sunday, October 26, 2025.
P5201 – Oral Vonoprazan Is Noninferior to Intravenous Proton Pump Inhibitors for Peptic Ulcer Rebleeding: A Matched Cohort Analysis of Clinical Outcomes
Tuesday, October 28, 2025 | 10:30 AM – 4:00 PM PDT | Exhibit Hall
Author Insight from Saqr Alsakarneh, MD, MS
What’s new here and important for clinicians?
Our study is the first large, real-world analysis to directly compare oral vonoprazan with intravenous (IV) proton pump inhibitors (PPIs) for secondary prevention of peptic ulcer rebleeding after endoscopic hemostasis. We found that oral vonoprazan is noninferior to IV PPI therapy in preventing 30-day rebleeding, while also being associated with significantly fewer hospital readmissions at both 1 and 3 months. This suggests that vonoprazan may offer clinicians an effective, convenient oral alternative to IV therapy, with potential downstream benefits for reducing health care utilization and cost.
What do patients need to know?
For patients with bleeding stomach or duodenal ulcers, the standard treatment after endoscopy is usually several days of IV medication in the hospital. Our findings show that an oral medication, vonoprazan, works just as well at preventing rebleeding. It may even lower the chances of needing to return to the hospital. This could mean shorter hospital stays, fewer readmissions, and an easier recovery process for patients, without compromising safety.
Author Contact
Saqr Alsakarneh, MD, MS
Mayo Clinic
Rochester, MN
alsakarneh.saqr [at] mayo.edu
For assistance contacting other ACG experts, please contact Becky Abel, ACG’s Senior Communications Manager, at mediaonly [at] gi.org.